PDS Biotechnology (PDSB)
(Delayed Data from NSDQ)
$3.27 USD
+0.01 (0.31%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $3.27 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
Price, Consensus and EPS Surprise
PDSB 3.27 +0.01(0.31%)
Will PDSB be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for PDSB based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PDSB
All You Need to Know About PDS Biotechnology (PDSB) Rating Upgrade to Buy
PDS Biotech's (PDSB) Shares Up 12% in a Month: Here's Why
PDSB: What are Zacks experts saying now?
Zacks Private Portfolio Services
PDS Biotech (PDSB) Up 32% on Interim Data From HPV Cancer Study
PDS Biotech (PDSB) Completes Enrollment for HPV Cancer Study
PDS Biotech (PDSB) Up on Data From HPV-Positive Cancer Study
Other News for PDSB
PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer
PDS Biotechnology to host KOL event on Phase 2 VERSATILE-002 trial
Hookipa Pharma: 04/25/24 Update Should Be The First Of Several Positive Catalysts
PDS Biotechnology price target lowered by $3 at B. Riley, here's why
Noble Financial Sticks to Its Buy Rating for PDS Biotechnology (PDSB)